NCT03132454 2025-11-03
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
89 trialsNCT01187199 2025-10-27
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT00639262 2025-05-02
Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
Thomas Jefferson University
Phase 1 Completed
NCT02298348 2025-02-17
N2013-02
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Active not recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02349867 2022-09-19
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
Virginia Commonwealth University
Phase 1 Completed
NCT00981162 2022-09-13
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Roswell Park Cancer Institute
Phase 1 Completed
NCT01724606 2022-03-07
Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00892658 2021-10-06
Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)
University Health Network, Toronto
Phase 1 Completed
NCT02292173 2021-06-10
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02642913 2021-03-05
Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01666756 2021-01-27
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
City of Hope Medical Center
Phase 1 Completed
NCT01197170 2021-01-22
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01531361 2021-01-22
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00823290 2020-12-14
Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)
University of Erlangen-Nürnberg Medical School
Phase 1 Terminated
NCT01561833 2020-08-13
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Yale University
Phase 1 Completed
NCT00543504 2020-06-30
Bevacizumab in Multiple Phase I Combinations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02989870 2020-06-05
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT02779283 2020-05-26
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 1 Completed
NCT02406521 2020-03-04
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01497444 2020-02-06
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT00954278 2019-11-15
Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer
University of Wisconsin, Madison
Phase 1 Completed
NCT02288507 2019-11-08
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Withdrawn
NCT00687674 2019-08-20
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Terminated
NCT01008917 2019-05-09
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
Phase 1 Completed
NCT01844947 2019-04-26
VINSOR
Karolinska University Hospital
Phase 1 Completed
NCT00610246 2019-02-15
A Study of Radiation With Sorafenib in Advanced Cancer
University Health Network, Toronto
Phase 1 Completed
NCT02412475 2019-01-24
Epigenetic Reprogramming in Relapse AML
Medical College of Wisconsin
Phase 1 Terminated
NCT00543335 2018-11-15
Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00734526 2018-11-09
Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02636426 2018-10-22
SOPRANO
Amsterdam UMC, location VUmc
Phase 1 Completed
NCT00822848 2018-09-07
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 1 Completed
NCT02035527 2018-05-24
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01893099 2018-04-23
Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT00908167 2018-01-12
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01011010 2018-01-05
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00703638 2017-11-29
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT02270788 2017-10-03
Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00572078 2017-09-25
Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors
Indiana University
Phase 1 Completed
NCT01276210 2017-07-17
Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT00943943 2017-03-29
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01398501 2017-03-22
Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant
Massachusetts General Hospital
Phase 1 Completed
NCT01005797 2017-03-03
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Medical University of South Carolina
Phase 1 Completed
NCT00418496 2017-02-20
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01640665 2016-09-16
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Yale University
Phase 1 Completed
NCT00846131 2016-09-15
Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma
Northwestern University
Phase 1 Completed
NCT01376453 2016-09-12
Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00627835 2016-07-20
Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
British Columbia Cancer Agency
Phase 1 Withdrawn
NCT01078961 2016-06-08
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Massachusetts General Hospital
Phase 1 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed